Original Article

Immunonutritional Biomarkers in Primary Sjögren’s Syndrome Disease Activity: CALLY Index and HALP Score

Volume 40 · Issue 3 · September 2025 Publish Date: September 1, 2025
Full Text PDF HTML
DOI
Ayşegül Özdoğan Bircan ORCID
Division of Rheumatology, Department of Internal Medicine, Çukurova University Faculty of Medicine, Adana, Türkiye image/svg+xml
Şerife Şeyda Zengin Acemoğlu ORCID
Division of Rheumatology, Department of Internal Medicine, Çukurova University Faculty of Medicine, Adana, Türkiye image/svg+xml
İpek Türk ORCID
Division of Rheumatology, Department of Internal Medicine, Çukurova University Faculty of Medicine, Adana, Türkiye image/svg+xml
Hüseyin Turgut Elbek Özer ORCID
Division of Rheumatology, Department of Internal Medicine, Çukurova University Faculty of Medicine, Adana, Türkiye image/svg+xml
Özdoğan Bircan, A., Zengin Acemoğlu, Şerife Şeyda, Türk, İpek, & Elbek Özer, H. T. (2025). Immunonutritional Biomarkers in Primary Sjögren’s Syndrome Disease Activity: CALLY Index and HALP Score. Archives of Rheumatology, 40(3), 376–384. https://doi.org/10.5152/ArchRheumatol.2025.25012
Full Text PDF HTML

Abstract

Background/Aims: Primary Sjögren’s syndrome (pSS) is an autoimmune disease that can affect several systems. The purpose of this study was to examine the connection between primary Sjögren’s disease activity and the CRP-albumin-lymphocyte index (CALLY) and the HALP (hemoglobin, albumin, lymphocyte, and platelet) score, 2 novel immunonutritional indicators that have not yet been applied to rheumatological disease activation.

Materials and Methods: This cross-sectional study included 89 patients with pSS and 113 age- and sex-matched individuals. The relationship between haematological, inflammatory, immunonutritional biomarkers, and disease activation was investigated, as were the differences between the groups.

Results: Eighty-nine patients (96.6% female, mean age 53.4 ± 15.0 years) and 113 control subjects (97.3% female, mean age 50.8 ± 14.9 years) were included in the study. The levels of C-reactive protein (CRP), erythrocyte sedimentation rate, red cell distribution width, neutrophil lymphocyte ratio, monocyte lymphocyte ratio, platelet lymphocyte ratio, and C-reactive protein albumin ratio were significantly higher in the group of patients with pSS compared to the control group (all; P < .001). Systemic immuneinflammation index and systemic inflammatory response index were significantly elevated in the patient cohort compared to the control group (P = .002 and P = .048, respectively). The CALLY index and HALP score were negatively correlated with EULAR Sjögren’s syndrome disease activity index (P < .001 for both).

Conclusion: The CALLY index and HALP score represent a novel approach to assessing disease activity and prognosis in a number of conditions, including stroke, myocardial infarction, osteoarthritis, pulmonary thromboembolism, asthma, chronic obstructive pulmonary disease, and many types of cancer. They may also be useful as a guide to disease activity and monitoring in pSS.

Similar Articles

Article Info
Published In
Journal Archives of Rheumatology
Volume / Issue Volume 40 · Issue 3 · September 2025
Pages 376-384
History
Published Online September 1, 2025
Copyright
Affiliations
1
Ayşegül Özdoğan Bircan ORCID
Division of Rheumatology, Department of Internal Medicine, Çukurova University Faculty of Medicine, Adana, Türkiye
2
Şerife Şeyda Zengin Acemoğlu ORCID
Division of Rheumatology, Department of Internal Medicine, Çukurova University Faculty of Medicine, Adana, Türkiye
3
İpek Türk ORCID
Division of Rheumatology, Department of Internal Medicine, Çukurova University Faculty of Medicine, Adana, Türkiye
4
Hüseyin Turgut Elbek Özer ORCID
Division of Rheumatology, Department of Internal Medicine, Çukurova University Faculty of Medicine, Adana, Türkiye
Cite this Article
Özdoğan Bircan, A., Zengin Acemoğlu, Şerife Şeyda, Türk, İpek, & Elbek Özer, H. T. (2025). Immunonutritional Biomarkers in Primary Sjögren’s Syndrome Disease Activity: CALLY Index and HALP Score. Archives of Rheumatology, 40(3), 376–384. https://doi.org/10.5152/ArchRheumatol.2025.25012
Share
Outlines